Edgewise Therapeutics (EWTX) Net Income towards Common Stockholders (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$49.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 20.14% year-over-year to -$49.0 million; the trailing twelve-month figure through Mar 2026 stood at -$431.7 million (down 4.15% YoY), and the FY2025 full-year result was -$423.5 million, down 5.56% from the prior year.
• Net Income towards Common Stockholders grew to -$49.0 million in Q1 2026, from -$305.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$16.5 million in Q2 2022 to a low of -$307.1 million in Q4 2024.
• A 5-year average of -$62.9 million and a median of -$32.6 million in 2024 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders jumped 40.27% in 2022 and tumbled 916.89% in 2024, its largest moves.
• Tracing EWTX's Net Income towards Common Stockholders over 5 years: stood at -$19.8 million in 2022, then plunged by 52.14% to -$30.2 million in 2023, then plunged by 916.89% to -$307.1 million in 2024, then grew by 0.36% to -$305.9 million in 2025, then jumped by 83.98% to -$49.0 million in 2026.
• Business Quant data shows EWTX's Net Income towards Common Stockholders at -$49.0 million in Q1 2026, -$305.9 million in Q4 2025, and -$40.7 million in Q3 2025.